---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-020563"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:07:35.511575+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AgeX Therapeutics amends secured note, extends draw period, draws $500K

## Summary
- Third Amendment extends draw period under secured convertible note to Oct 31, 2023 (or earlier if a Qualified Offering occurs).
- Drew $500,000 on June 7, 2023; repayment due February 14, 2024.
- Amendment waives warrant issuance for prior $4M commitment draws under Second Amendment.
- Extends Reverse Financing Condition deadline for subsidiary Reverse Bioengineering to June 20, 2023.

## SEC filing metadata
- accession: 0001493152-23-020563
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223020563/0001493152-23-020563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223020563/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-020563
- JSON: https://secwatch.observer/filing/0001493152-23-020563.json
- Plain text: https://secwatch.observer/filing/0001493152-23-020563.txt

## Key facts
- Debt Financings
  Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Ltd maturing February 14, 2024.
  - Instrument: convertible notes
  - Principal: $500,000
  - Counterparty: Juvenescence Ltd
  - Maturity: February 14, 2024
  - Event: incurrence
  source text: On June 7, 2023, AgeX drew $500,000 of its credit available under the Secured Note as most recently amended by the Third Amendment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223020563/0001493152-23-020563-index.htm
- Material Agreements
  Serina Therapeutics, Inc. amended Third Amendment to Amended and Restated Convertible Promissory Note with Juvenescence Limited (effective 2023-06-02).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: Juvenescence Limited
  - Effective: 2023-06-02
  source text: On June 2, 2023 AgeX and Juvenescence Limited (“Juvenescence”) entered into an amendment to the Amended and Restated Secured Convertible Promissory Note (the “Secured Note”), as previously amended by an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”), to provide that (i) AgeX may draw on the available portion of the line of credit under the Secured Note until the earlier of the date a Qualified Offering as defined in the Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition is amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223020563/0001493152-23-020563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.